JP5105696B2 - アンジオポエチン様タンパク質３Ａｎｇｐｔｌ３含有組成物とその使用方法 - Google Patents

アンジオポエチン様タンパク質３Ａｎｇｐｔｌ３含有組成物とその使用方法 Download PDF

Info

Publication number
JP5105696B2
JP5105696B2 JP2003545797A JP2003545797A JP5105696B2 JP 5105696 B2 JP5105696 B2 JP 5105696B2 JP 2003545797 A JP2003545797 A JP 2003545797A JP 2003545797 A JP2003545797 A JP 2003545797A JP 5105696 B2 JP5105696 B2 JP 5105696B2
Authority
JP
Japan
Prior art keywords
angptl3
liver
acid sequence
amino acid
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003545797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005521643A5 (enExample
JP2005521643A (ja
Inventor
フェララ，ナポレオン
ガーバー，ハンス−ピーター
コワルスキー，ジョー
ピサバロー，マリア，テレサ
シャーマン，ダニエル，エリック
Original Assignee
ジェネンテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネンテック， インコーポレイテッド filed Critical ジェネンテック， インコーポレイテッド
Publication of JP2005521643A publication Critical patent/JP2005521643A/ja
Publication of JP2005521643A5 publication Critical patent/JP2005521643A5/ja
Application granted granted Critical
Publication of JP5105696B2 publication Critical patent/JP5105696B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
JP2003545797A 2001-11-16 2002-11-13 アンジオポエチン様タンパク質３Ａｎｇｐｔｌ３含有組成物とその使用方法 Expired - Fee Related JP5105696B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33242901P 2001-11-16 2001-11-16
US60/332,429 2001-11-16
PCT/US2002/036865 WO2003044172A2 (en) 2001-11-16 2002-11-13 Composition comprising and method of using angiopoietin-like protein 3 angptl3

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009259497A Division JP2010100624A (ja) 2001-11-16 2009-11-13 アンジオポエチン様タンパク質３Ａｎｇｐｔｌ３含有組成物とその使用方法

Publications (3)

Publication Number Publication Date
JP2005521643A JP2005521643A (ja) 2005-07-21
JP2005521643A5 JP2005521643A5 (enExample) 2006-04-06
JP5105696B2 true JP5105696B2 (ja) 2012-12-26

Family

ID=23298191

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003545797A Expired - Fee Related JP5105696B2 (ja) 2001-11-16 2002-11-13 アンジオポエチン様タンパク質３Ａｎｇｐｔｌ３含有組成物とその使用方法
JP2009259497A Pending JP2010100624A (ja) 2001-11-16 2009-11-13 アンジオポエチン様タンパク質３Ａｎｇｐｔｌ３含有組成物とその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009259497A Pending JP2010100624A (ja) 2001-11-16 2009-11-13 アンジオポエチン様タンパク質３Ａｎｇｐｔｌ３含有組成物とその使用方法

Country Status (14)

Country Link
US (3) US7267819B2 (enExample)
EP (1) EP1451578B1 (enExample)
JP (2) JP5105696B2 (enExample)
KR (2) KR20100029861A (enExample)
CN (2) CN1615440A (enExample)
AU (1) AU2002348286B2 (enExample)
CA (1) CA2464542C (enExample)
ES (1) ES2429034T3 (enExample)
IL (2) IL161542A0 (enExample)
MX (1) MXPA04004609A (enExample)
NO (1) NO336021B1 (enExample)
NZ (1) NZ532852A (enExample)
WO (1) WO2003044172A2 (enExample)
ZA (1) ZA200403070B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ES2429034T3 (es) 2001-11-16 2013-11-12 Genentech, Inc. Uso de antagonistas de ANGPTL3 para el tratamiento de enfermedades hepáticas
AU2004266043B2 (en) * 2003-08-21 2007-09-20 Duchesnay Inc. Micronutrient supplement
CA2574791A1 (en) * 2004-07-20 2006-02-09 Genentech, Inc. Compositions and methods of using angiopoietin-like 4 protein
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
EP1771474B1 (en) 2004-07-20 2010-01-27 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
US7807645B2 (en) 2005-09-23 2010-10-05 The Regents Of The University Of California Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment
WO2008073300A2 (en) * 2006-12-08 2008-06-19 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
US8354111B2 (en) 2008-04-14 2013-01-15 Hadasit Medical Research Services And Development Ltd. Stable cell binding chimeric peptides
CN101852805B (zh) * 2009-03-31 2015-04-01 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
PT2453921E (pt) 2009-07-14 2015-09-25 Novartis Ag Diferenciação de células estaminais mesenquimais
CN111700901A (zh) 2010-01-08 2020-09-25 Ionis制药公司 血管生成素样3表达的调节
AU2015200969A1 (en) * 2010-01-08 2015-03-19 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
EP2517028B1 (en) * 2010-02-02 2017-12-13 Arizona Board Of Regents Controlled tunnel gap device for sequencing polymers
EP2668499A4 (en) * 2011-01-29 2015-05-27 Astute Medical Inc METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
JP6249447B2 (ja) 2012-01-24 2017-12-20 インターケー・ペプチド・セラピューティクス・リミテッド 癌治療用ペプチド剤
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation
CN104062432B (zh) * 2013-03-22 2016-01-20 中山大学 ang2在制备ECTC血管类型肝癌诊断试剂及治疗药物中的应用
CA2921162A1 (en) 2013-05-01 2014-11-06 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
HUE052243T2 (hu) 2013-12-24 2021-04-28 Ionis Pharmaceuticals Inc Az angiopoietin-szerû 3 expressziójának modulációja
MX382230B (es) 2014-05-01 2025-03-13 Ionis Pharmaceuticals Inc Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3.
CN105021827B (zh) * 2015-07-17 2016-09-28 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
EP3370708A4 (en) 2015-11-06 2019-06-26 Ionis Pharmaceuticals, Inc. MODULATION OF APOLIPOPROTEIN (A) EXPRESSION
EP3411392B1 (en) * 2016-02-04 2021-12-29 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered angptl8 gene
MX2018010401A (es) 2016-03-03 2019-03-06 Regeneron Pharma Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3.
PE20201287A1 (es) * 2017-09-14 2020-11-24 Arrowhead Pharmaceuticals Inc Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
WO2020099482A2 (en) * 2018-11-13 2020-05-22 Lipigon Pharmaceuticals Ab Angptl 3 oligonucleotides influencing the regulation of the fatty acid metabolism
TWI747098B (zh) * 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
EP3993820A4 (en) * 2019-07-04 2023-08-16 Cadila Healthcare Limited VACCINE BASED ON ANGPTL3 FOR THE TREATMENT OF LIVER DISEASES
CN111122872B (zh) * 2019-11-20 2023-01-20 中山大学附属第一医院 血管生成素样蛋白7在心力衰竭预后评估中的应用
CN110938144B (zh) * 2019-11-27 2022-07-26 复旦大学附属儿科医院 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途
US20240141029A1 (en) * 2021-03-05 2024-05-02 Anji Pharmaceuticals Inc. Methods and compositions for treating sepsis
CN114934021B (zh) * 2022-04-21 2023-08-08 复旦大学附属儿科医院 一种Angptl3敲除的鼠永生化足细胞系及其应用
CN120254294B (zh) * 2025-06-05 2025-09-09 南昌大学第一附属医院 Angptl3在乙肝相关慢加急性肝衰竭预后中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596850B1 (en) * 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
EP0917878A4 (en) 1997-02-26 2004-05-19 Toray Industries REMEDIES FOR HEPATITIS
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
WO1999055869A1 (en) * 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
JP2002533058A (ja) * 1998-05-12 2002-10-08 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ９７個のヒト分泌タンパク質
WO1999067382A2 (en) * 1998-06-24 1999-12-29 Compugen Ltd. Angiopoietin-like growth factor sequences
KR100553300B1 (ko) 1999-03-08 2006-02-20 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
ES2429034T3 (es) 2001-11-16 2013-11-12 Genentech, Inc. Uso de antagonistas de ANGPTL3 para el tratamiento de enfermedades hepáticas

Also Published As

Publication number Publication date
KR20100029861A (ko) 2010-03-17
CA2464542A1 (en) 2003-05-30
CN1615440A (zh) 2005-05-11
CN101905024A (zh) 2010-12-08
WO2003044172A3 (en) 2003-11-20
IL203894A (en) 2013-09-30
US20070134250A1 (en) 2007-06-14
EP1451578A4 (en) 2006-02-01
ES2429034T3 (es) 2013-11-12
JP2005521643A (ja) 2005-07-21
EP1451578A2 (en) 2004-09-01
JP2010100624A (ja) 2010-05-06
CA2464542C (en) 2015-01-20
IL161542A0 (en) 2004-09-27
WO2003044172B1 (en) 2004-03-18
NO20042410L (no) 2004-06-09
EP1451578B1 (en) 2013-08-21
US7267819B2 (en) 2007-09-11
US20030215451A1 (en) 2003-11-20
AU2002348286B2 (en) 2008-04-03
US20090098117A1 (en) 2009-04-16
NZ532852A (en) 2006-08-31
ZA200403070B (en) 2005-06-29
KR101012904B1 (ko) 2011-02-08
AU2002348286A1 (en) 2003-06-10
MXPA04004609A (es) 2004-08-12
WO2003044172A2 (en) 2003-05-30
KR20050044485A (ko) 2005-05-12
US8541376B2 (en) 2013-09-24
NO336021B1 (no) 2015-04-20

Similar Documents

Publication Publication Date Title
CA2464542C (en) Composition comprising and method of using angiopoietin-like protein 3 angptl3
EP1196186B1 (en) Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
EP1259248B1 (en) Methods for treating cancers expressing vascular endothelial growth factor d
US20080241835A1 (en) Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
KR100543730B1 (ko) 종양 괴사 인자 관련 리간드
SK3532000A3 (en) Dna sequence coding for kay ligand, method for the preparation of kay ligand, pharmaceutical composition containing said ligand and the use thereof
JP2012246296A (ja) 血管形成及び心血管疾患の調節に使用する肝細胞成長因子の新規インヒビター
JP2002530062A (ja) １２個のヒト分泌タンパク質
EP1519193B1 (en) Methods for detecting cancers expressing vascular endothelial growth factor D
EP1212417B1 (en) Promotion or inhibition of angiogenesis and cardiovascularization
AU5920099A (en) Promotion or inhibition of angiogenesis and cardiovascularization
HK1077877A (en) Composition comprising and method of using angiopoietin-like protein 3 angptl3
KR100961345B1 (ko) Ｅｇ-ｖｅｇｆ 핵산 및 폴리펩티드 및 사용 방법
AU2006201128A1 (en) Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor D

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100218

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100301

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120621

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120727

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121002

R150 Certificate of patent or registration of utility model

Ref document number: 5105696

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151012

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees